{"product_id":"fch-pet-ct-imaging-for-parathyroid-gland-detection-a-patients-guide-to-modern-pre-surgical-scanning","title":"FCH PET\/CT Imaging for Parathyroid Gland Detection: A Patient's Guide to Modern Pre-Surgical Scanning","description":"\u003cp\u003eResearchers reviewed over a decade of evidence on a modern imaging technique called FCH PET\/CT, which uses a radioactive tracer to pinpoint overactive parathyroid glands before surgery. The procedure detects abnormal parathyroid glands with about 97% sensitivity overall, outperforming both ultrasound (47% positivity) and traditional MIBI scintigraphy (37% positivity) in real-world settings. For patients with primary hyperparathyroidism, this imaging method enables minimally invasive surgery, reduces the risk of failed operations, and has proven cost-effective in both the United States and Europe. The authors recommend FCH PET\/CT as the first-line radionuclide imaging technique for all patients with hyperparathyroidism who are candidates for surgery.\u003c\/p\u003e\n\n\u003ch1\u003eFCH PET\/CT Imaging for Parathyroid Gland Detection: A Patient's Guide to Modern Pre-Surgical Scanning\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Hyperparathyroidism and the Parathyroid Glands\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#imaging-history\"\u003eThe Evolution of Parathyroid Imaging\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#how-fch-works\"\u003eHow FCH PET\/CT Works: The Science Explained\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eHow This Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: How Well Does FCH PET\/CT Perform?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#multiglandular\"\u003eDetecting Multiple Gland Disease\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#persistent\"\u003eImaging After Failed or Previous Surgery\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#carcinoma\"\u003eRare Cases: Parathyroid Carcinoma\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cost\"\u003eCost-Effectiveness: Is It Worth It?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFCH PET\/CT detects abnormal parathyroid glands with about 97% sensitivity, outperforming ultrasound (47%) and MIBI (37%) in real-world settings.\u003c\/li\u003e\n\u003cli\u003eIn a randomized trial, FCH-guided surgery achieved normal calcium at one month in 85% of patients versus 56% with MIBI guidance.\u003c\/li\u003e\n\u003cli\u003eFCH PET\/CT detects multiple gland disease better than MIBI, reducing the risk of a missed gland and repeat surgery.\u003c\/li\u003e\n\u003cli\u003eFor recurrent or persistent hyperparathyroidism after surgery, FCH PET\/CT had 78% positivity, similar to first-time surgery, and outperformed 4D-CT.\u003c\/li\u003e\n\u003cli\u003eCost-effectiveness models in the US and Netherlands found FCH PET\/CT worthwhile despite higher imaging costs, because it prevents failed operations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Hyperparathyroidism and the Parathyroid Glands\u003c\/h2\u003e\n\n\u003cp\u003eHyperparathyroidism (HPT) is a condition in which one or more of the parathyroid glands produce too much parathyroid hormone (PTH). These four small glands — two superior and two inferior — are normally located behind the thyroid gland in the neck. They regulate calcium levels in your blood. When they become overactive (hyperfunctioning), calcium levels rise, which can lead to kidney stones, bone thinning, fatigue, and other health problems.\u003c\/p\u003e\n\n\u003cp\u003eAnatomical studies show that \u003cstrong\u003e81.4% of people have exactly four parathyroid glands\u003c\/strong\u003e (two superior and two inferior). Interestingly, five or more glands are found in \u003cstrong\u003e4.9% of healthy individuals and 6.3% of patients with HPT\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe location of these glands matters greatly for surgery. The superior glands, which develop from the 4th pharyngeal pouch, usually stay close to the upper pole of the thyroid. In less than 1% of cases, they migrate above the upper thyroid pole. The inferior glands, which develop from the 3rd pharyngeal pouch, travel much farther during embryonic development — potentially from the angle of the jaw all the way down to the heart sac (pericardium). In approximately 2% of cases, these inferior glands end up above the upper thyroid pole.\u003c\/p\u003e\n\n\u003cp\u003eBecause of this wide range of travel, parathyroid glands can end up in unexpected places called \"ectopic\" locations. According to a recent meta-analysis cited in this article:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e15.9%\u003c\/strong\u003e of parathyroid glands are in ectopic locations\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e11.6%\u003c\/strong\u003e are ectopic but still in the neck, including:\n    \u003cul\u003e\n      \u003cli\u003e3.6% in the retroesophageal\/paraesophageal space (behind the esophagus)\u003c\/li\u003e\n      \u003cli\u003e2.4% inside the thyroid gland itself\u003c\/li\u003e\n      \u003cli\u003e2.1% in the carotid sheath (around the major neck artery)\u003c\/li\u003e\n      \u003cli\u003e2.0% in the thyrothymic ligament\u003c\/li\u003e\n      \u003cli\u003e0.6% in the tracheoesophageal groove (between windpipe and esophagus)\u003c\/li\u003e\n      \u003cli\u003e1.0% in other neck locations\u003c\/li\u003e\n    \u003c\/ul\u003e\n  \u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4.3%\u003c\/strong\u003e are in the mediastinum (the area between the lungs), most commonly within the thymus gland\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis is why accurate preoperative imaging is essential — it helps surgeons know exactly where to look. With modern preoperative localization studies, the rate of failed parathyroidectomy (PTX) surgery, particularly due to unsuspected multiple-gland disease or ectopic glands, has dropped dramatically.\u003c\/p\u003e\n\n\u003ch2 id=\"imaging-history\"\u003eThe Evolution of Parathyroid Imaging\u003c\/h2\u003e\n\n\u003cp\u003eDoctors have long known that combining an anatomical imaging method with a functional one gives the best results for parathyroid surgery planning. The history of parathyroid imaging shows steady progress over four decades:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe 1980s:\u003c\/strong\u003e Thallium-201 (201Tl) scanning was used, combined with technetium-99m-pertechnetate to subtract thyroid activity. In one operated series, the success rate reached 92% among 24 patients, but two of four sub-centimeter abnormal glands were missed. Thallium had poor imaging characteristics, including suboptimal photon energy (69-81 keV) and a long physical half-life of 73 hours, exposing patients to unacceptably high whole-body radiation. \u003cstrong\u003e201Tl is no longer recommended for parathyroid imaging.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLate 1980s onward:\u003c\/strong\u003e Technetium-99m-sestaMIBI (MIBI) scintigraphy became the standard functional imaging method. Over the years, it was refined with dual-phase studies, thyroid uptake subtraction with 99mTc-pertechnetate or preferably 123I, and eventually SPECT\/CT (single photon emission computed tomography combined with X-ray CT).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe PET era:\u003c\/strong\u003e Positron emission tomography (PET) offers better image resolution than SPECT. In 1964, methionine labeled with 75Se was tried, then abandoned. Thirty years later, 11C-methionine was proposed for PET imaging of parathyroid glands. However, evidence showed it was less effective than a fluorinated choline analog called \u003cstrong\u003e18F-fluorocholine (FCH)\u003c\/strong\u003e, introduced for this purpose in 2014. In the same year, 11C-choline was also reported as a PET tracer for parathyroid adenoma localization in 40 patients. A comparative study of 32 patients with negative first-line imaging found 11C-choline PET\/CT superior to 11C-methionine. In 12 of 14 patients where FCH PET\/CT had been negative or inconclusive, 11C-choline identified a suspicious lesion.\u003c\/p\u003e\n\n\u003cp\u003eHowever, 11C-labeled tracers have a very short half-life of just 20 minutes. This means lower radiation exposure for patients — but it requires an on-site cyclotron and a GMP radiopharmacy facility, which is logistically difficult and available in very few PET centers. \u003cstrong\u003eFCH, by contrast, is widely available\u003c\/strong\u003e with no such infrastructure requirements.\u003c\/p\u003e\n\n\u003ch2 id=\"how-fch-works\"\u003eHow FCH PET\/CT Works: The Science Explained\u003c\/h2\u003e\n\n\u003cp\u003eCholine is a natural compound that all cells need to build phospholipids — the essential building blocks of cell membranes. When choline enters a cell, the enzyme choline kinase converts it to phosphorylcholine, which eventually becomes phosphatidylcholine (lecithin), a key membrane component.\u003c\/p\u003e\n\n\u003cp\u003eFCH is a fluorinated version of choline that closely follows the same metabolic pathway. Cancer cells and overactive parathyroid cells have increased choline kinase activity, which is why they take up FCH more avidly than normal tissues. This \"hot spot\" of radioactivity can then be seen on the PET scan.\u003c\/p\u003e\n\n\u003cp\u003eFCH has been used in Europe for more than 20 years, primarily for detecting prostate and hepatocellular carcinoma. In 2010, it received marketing authorization in France for oncologic imaging. It was initially approved for parathyroid imaging in France in January 2024. Interestingly, over a decade ago, several European teams noticed incidental \"hot spots\" on FCH PET\/CT scans performed for prostate cancer — these turned out to be overactive parathyroid glands. Some of those patients had undiagnosed HPT, which was then confirmed, and surgery confirmed that the FCH focus matched an abnormal parathyroid gland.\u003c\/p\u003e\n\n\u003cp\u003eThe European Association of Nuclear Medicine (EANM) now explicitly recommends FCH PET\/CT for detecting abnormal parathyroid glands in its 2021 guideline on parathyroid imaging.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eHow This Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis article is a comprehensive review that combines published evidence with the authors' real-world experience. The team analyzed data from their own institutions — Hôpital Tenon in Paris, France, where they have used FCH PET\/CT for parathyroid imaging for \u003cstrong\u003e12 years\u003c\/strong\u003e, and Bratislava, Slovakia, where they have used it for \u003cstrong\u003e11 years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe review covers multiple study types, including randomized controlled trials, retrospective analyses, and prospective cohort studies. Key studies analyzed include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe APACH2 randomized trial comparing FCH PET\/CT head-to-head with MIBI SPECT\/CT\u003c\/li\u003e\n  \u003cli\u003eA partial retrospective analysis of 323 FCH PET\/CT scans for primary HPT (pHPT) and 78 for renal HPT (rHPT) from Hôpital Tenon\u003c\/li\u003e\n  \u003cli\u003eA retrospective study by Broos et al. of 271 patients undergoing first-line FCH PET\/CT\u003c\/li\u003e\n  \u003cli\u003eA prospective study by Cuderman et al. of 103 patients who underwent both FCH PET\/CT and MIBI scintigraphy\u003c\/li\u003e\n  \u003cli\u003eCost-effectiveness modeling studies from both US and Dutch healthcare systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: How Well Does FCH PET\/CT Perform?\u003c\/h2\u003e\n\n\u003cp\u003eThe headline finding is striking: FCH PET\/CT has a \u003cstrong\u003esensitivity of 97% (range 96%-98%)\u003c\/strong\u003e for detecting abnormal parathyroid glands in primary HPT. This consistently outperforms other radiopharmaceuticals, ultrasound, and 4D-CT.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePositivity rates in the Hôpital Tenon series:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFCH PET\/CT as first-line imaging: \u003cstrong\u003e67% positivity\u003c\/strong\u003e (CI: 56-76) in 96 examinations\u003c\/li\u003e\n  \u003cli\u003eFCH PET\/CT performed later in the work-up: \u003cstrong\u003e75% positivity\u003c\/strong\u003e (CI: 70-80) in 305 examinations\u003c\/li\u003e\n  \u003cli\u003eMIBI scintigraphy: \u003cstrong\u003e37% positivity\u003c\/strong\u003e (CI: 30-44)\u003c\/li\u003e\n  \u003cli\u003eUltrasound: \u003cstrong\u003e47% positivity\u003c\/strong\u003e (CI: 42-52)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe lower rates for MIBI and ultrasound were influenced by selection bias — patients were typically referred for FCH PET\/CT specifically because MIBI and ultrasound had been inconclusive or discordant. Even so, FCH performed better.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroos et al. — first-line FCH PET\/CT in 271 patients with pHPT:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePositivity rate: \u003cstrong\u003e75%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eCorrect detection rate: \u003cstrong\u003e96% patient-based\u003c\/strong\u003e and \u003cstrong\u003e90% lesion-based\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAnother recent study of 271 patients with overt pHPT reported:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSensitivity: \u003cstrong\u003e99%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eSpecificity: \u003cstrong\u003e91%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003ePositive predictive value (PPV): \u003cstrong\u003e100%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eNegative predictive value (NPV): \u003cstrong\u003e80%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eAccuracy: \u003cstrong\u003e99%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe APACH2 randomized trial:\u003c\/strong\u003e In this trial, 57 patients with pHPT who needed functional imaging before their first parathyroidectomy were randomized: 29 to FCH PET\/CT and 28 to MIBI SPECT\/CT.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePositivity rate: \u003cstrong\u003e83% (24\/29) for FCH\u003c\/strong\u003e vs \u003cstrong\u003e64% (18\/28) for MIBI\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eSensitivity: \u003cstrong\u003e82% (CI: 62-93) for FCH\u003c\/strong\u003e vs \u003cstrong\u003e63% (CI: 42-80) for MIBI\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eNormal calcium levels one month after imaging-guided minimally invasive surgery: \u003cstrong\u003e85% (23\/27) in the FCH group\u003c\/strong\u003e vs \u003cstrong\u003e56% (14\/25) in the MIBI group\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis last point is critically important for patients — it means that when FCH PET\/CT guided the surgery, the operation was more likely to successfully cure the disease, with normal calcium levels achieved in a substantially higher proportion of patients one month after surgery.\u003c\/p\u003e\n\n\u003ch2 id=\"multiglandular\"\u003eDetecting Multiple Gland Disease (MGD)\u003c\/h2\u003e\n\n\u003cp\u003eMultiple gland disease (MGD) — the presence of more than one overactive parathyroid gland — occurs in \u003cstrong\u003e15% to 20% of primary HPT patients\u003c\/strong\u003e. This is a high-risk situation because if surgery removes only the one visible abnormal gland (minimally invasive parathyroidectomy), the remaining abnormal glands can cause disease recurrence.\u003c\/p\u003e\n\n\u003cp\u003eIn the Hôpital Tenon analysis, \u003cstrong\u003e29 of 167 pHPT patients (17%) had histologically proven MGD\u003c\/strong\u003e. Of these 29 patients, 21 (72%) underwent FCH PET\/CT because MIBI and ultrasound had been inconclusive or discordant. Given this strong selection bias, the patient-based sensitivity for MGD was \u003cstrong\u003e38% for FCH vs 0% for MIBI\u003c\/strong\u003e — MIBI failed to detect any case of MGD in this group. In fact, 38% of MGD cases appeared as a single abnormal focus on MIBI SPECT, with discordant ultrasound results. In those patients, a MIBI-based strategy would not have prompted FCH PET\/CT to detect the additional abnormal glands.\u003c\/p\u003e\n\n\u003cp\u003eOther studies confirm FCH's superiority in MGD:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOne short series found that four MGDs among 17 pHPT patients appeared as a single focus on scintigraphy in three cases, whereas FCH correctly localized six abnormal glands in three patients, leading to successful surgery.\u003c\/li\u003e\n  \u003cli\u003eAnother study reported that \u003cstrong\u003e9 of 15 MGDs were recognized on FCH PET\/CT vs only 4 on MIBI scintigraphy\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eThe prospective study by Cuderman et al. included 103 patients with pHPT who underwent both FCH PET\/CT and MIBI scintigraphy with a comprehensive protocol. Histology revealed \u003cstrong\u003e14 patients (14%) with MGD\u003c\/strong\u003e, consisting of 4 dual adenomas and 31 hyperplastic glands. In this subgroup, FCH PET\/CT had a sensitivity of \u003cstrong\u003e88% and specificity of 100%\u003c\/strong\u003e, whereas MIBI scintigraphy had a sensitivity of only \u003cstrong\u003e44%\u003c\/strong\u003e. FCH PET\/CT revealed MGD in \u003cstrong\u003e6 of 14 patients (43%)\u003c\/strong\u003e who had been falsely classified as having a single abnormal gland on MIBI.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFCH is also particularly good at detecting hyperplastic parathyroid glands (enlarged but not adenomatous glands), which are notoriously difficult to find with MIBI and ultrasound. In a series localizing \u003cstrong\u003e155 hyperplastic parathyroid glands\u003c\/strong\u003e, the sensitivity of FCH PET\/CT was \u003cstrong\u003e72%, versus 39% for ultrasound and 25% for MIBI\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with renal (secondary) HPT, FCH is even more valuable. In the Hôpital Tenon series, MGD was expected and detected by FCH PET\/CT in \u003cstrong\u003e88% of patients with renal HPT\u003c\/strong\u003e. This matters because renal HPT patients almost always have multiple overactive glands.\u003c\/p\u003e\n\n\u003cp\u003eAnother study of 64 patients with positive MIBI scans found that subsequent FCH PET\/CT identified \u003cstrong\u003enine additional abnormal glands not detected by MIBI in eight patients (12.5%)\u003c\/strong\u003e, including 4 patients with MGD. Additionally, a negative FCH PET\/CT allowed reassessment of \u003cstrong\u003eeight false-positive MIBI results in seven patients (11%)\u003c\/strong\u003e. Only one abnormal gland was missed by FCH and correctly identified by MIBI.\u003c\/p\u003e\n\n\u003cp\u003eGiven these findings, the authors state that first-line FCH PET\/CT is especially indicated when there is a high likelihood of hyperplastic glands, including persistent or recurrent primary HPT related to MGD, renal HPT, and hereditary HPT, particularly multiple endocrine neoplasia type 1 (MEN1).\u003c\/p\u003e\n\n\u003ch2 id=\"persistent\"\u003eImaging After Failed or Previous Surgery\u003c\/h2\u003e\n\n\u003cp\u003eWhen HPT persists or recurs after parathyroidectomy, finding the remaining abnormal gland(s) is crucial before recommending reoperation, because repeat surgery carries a high risk of complications. The Hôpital Tenon data showed that FCH PET\/CT performed nearly identically in this challenging setting:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePatient-based positivity: \u003cstrong\u003e78% (42\/54)\u003c\/strong\u003e in patients with suspected persistence\/recurrence vs \u003cstrong\u003e84% (291\/347)\u003c\/strong\u003e in patients without prior surgery — not a statistically significant difference\u003c\/li\u003e\n  \u003cli\u003eGland-based sensitivity: \u003cstrong\u003e89% (24\/27)\u003c\/strong\u003e vs \u003cstrong\u003e91% (169\/186)\u003c\/strong\u003e — again, no significant difference\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFCH PET\/CT also outperformed 4D-CT in this setting. In a study by Latgé et al., \u003cstrong\u003e37 patients with persistent or recurrent pHPT\u003c\/strong\u003e underwent both FCH PET\/CT and 4D-contrast-enhanced CT (4D-CeCT):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFCH PET\/CT: \u003cstrong\u003e88% positivity rate and 95% sensitivity\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e4D-CeCT: \u003cstrong\u003e63% positivity rate and 70% sensitivity\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eDynamic 4D-CeCT identified no additional glands missed by PET\/CT\u003c\/li\u003e\n  \u003cli\u003eCombining the two techniques did not improve detection or sensitivity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors therefore conclude that \u003cstrong\u003erecurrent or persistent HPT after parathyroidectomy is a clear indication for FCH PET\/CT\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"carcinoma\"\u003eRare Cases: Parathyroid Carcinoma\u003c\/h2\u003e\n\n\u003cp\u003eIn rare cases, persistent pHPT after surgery is caused by parathyroid carcinoma — a rare malignant endocrine tumor. According to the \"3+3 rule\" and a recent review, malignant pHPT should be suspected when:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSerum PTH levels are \u003cstrong\u003e3 to 10 times above the upper limit of normal\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eCalcium levels are markedly elevated (\u003cstrong\u003egreater than 3 mmol\/L\u003c\/strong\u003e)\u003c\/li\u003e\n  \u003cli\u003eLesion size is \u003cstrong\u003egreater than 3 cm\u003c\/strong\u003e, possibly palpable in the neck\u003c\/li\u003e\n  \u003cli\u003eUltrasound shows inhomogeneous, hypoechoic, and lobulated masses\u003c\/li\u003e\n  \u003cli\u003eSevere bone disease (osteitis fibrosa cystica) or kidney disease (renal stones and nephrocalcinosis) is present\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eParathyroid carcinoma tends to recur and metastasize, so routine postoperative follow-up is essential. FCH PET\/CT was first reported in 2015 in a patient with recurrent parathyroid carcinoma, where it detected disease better than FDG PET\/CT and various scintigraphic methods. Subsequent case reports confirmed that both FCH and FDG PET\/CT can detect recurrent parathyroid carcinoma lesions, as well as synchronous recurrence of another malignancy. The authors note that FCH PET\/CT guides surgeons to perform selective metastasectomy in these cases.\u003c\/p\u003e\n\n\u003ch2 id=\"cost\"\u003eCost-Effectiveness: Is FCH PET\/CT Worth It?\u003c\/h2\u003e\n\n\u003cp\u003eAlthough FCH is more expensive per dose than MIBI, recent studies show the procedure is still cost-effective because of its superior diagnostic performance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eYap et al. — US healthcare system model:\u003c\/strong\u003e This decision-tree analysis modeled patients undergoing parathyroidectomy for pHPT using one of four preoperative localization approaches: FCH PET\/CT, 4D-CT, ultrasound, or MIBI SPECT.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFCH PET\/CT gained the most quality-adjusted life-years (QALYs): \u003cstrong\u003e23.9\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eIt was also the costliest imaging procedure at \u003cstrong\u003e$2,096\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eHowever, the total treatment cost was \u003cstrong\u003e$11,245, or $470 per quality-adjusted life-year gained\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eMIBI SPECT and ultrasound were \"dominated strategies\" — meaning they were both less effective and more costly overall\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eVan Mossel et al. — Dutch healthcare system:\u003c\/strong\u003e This study compared two strategies: a \"one-stop shop\" approach with FCH PET\/CT for all patients vs using FCH PET\/CT only after negative or inconclusive MIBI SPECT\/CT. Simulated long-term health effects and costs were \u003cstrong\u003esimilar for both strategies\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also note that the argument about limited PET scanner availability is becoming less valid with the rapid global expansion of PET technology.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor patients with confirmed hyperparathyroidism who are scheduled for surgery, this research has several meaningful implications.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBetter surgical outcomes:\u003c\/strong\u003e The APACH2 trial's finding — 85% of FCH-guided patients achieved normal calcium at one month vs 56% of MIBI-guided patients — translates directly into fewer failed operations and fewer repeat surgeries.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMore minimally invasive surgery:\u003c\/strong\u003e Accurate localization allows more patients to undergo minimally invasive parathyroidectomy (MIPTX), which shortens operative time, reduces incision length, and lowers surgical risks compared with traditional bilateral neck exploration.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFewer missed glands:\u003c\/strong\u003e FCH PET\/CT detects multiple gland disease far better than MIBI. This reduces the chance that a patient will need a second operation for an abnormal gland that was missed the first time.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLower cumulative radiation:\u003c\/strong\u003e Compared with undergoing both MIBI SPECT\/CT and then FCH PET\/CT sequentially, a single FCH PET\/CT means shorter patient mobilization and lower overall radiation exposure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCaution on blood test levels:\u003c\/strong\u003e The article notes that while higher serum PTH levels tend to produce clearer FCH PET results, researchers could not determine reliable cutoff values for PTH or calcium that would predict a positive or negative FCH scan. Interestingly, in 2011 studies, \u003cstrong\u003e5.5-7% of pHPT patients undergoing surgery had normal basal PTH levels\u003c\/strong\u003e. For patients with suggestive symptoms but normal PTH and calcium, a calcium load test can help confirm the diagnosis, and FCH PET\/CT remains a useful tool in this \"mild\" HPT setting.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eWhat This Study Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eAs with any review, there are limitations to acknowledge.\u003c\/p\u003e\n\n\u003cp\u003eMuch of the evidence comes from retrospective, real-world series with inherent selection bias — patients were often referred for FCH PET\/CT precisely because MIBI and ultrasound had failed. This bias likely understates FCH's true performance relative to older methods in unselected patients.\u003c\/p\u003e\n\n\u003cp\u003eThe evidence for FCH PET\/CT in \u003cstrong\u003erenal HPT\u003c\/strong\u003e is based on fewer series than for primary HPT, so the strength of the recommendation is somewhat lower in that setting.\u003c\/p\u003e\n\n\u003cp\u003eThe authors could not identify clinical or biochemical parameters (like specific PTH or calcium cutoff values) that would reliably predict who benefits most from FCH PET\/CT.\u003c\/p\u003e\n\n\u003cp\u003eFinally, while the review draws on over a decade of real-world experience, most comparative data against MIBI come from a single randomized controlled trial (APACH2) with a relatively small sample size of 57 patients.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this comprehensive review, here is the practical guidance that emerges:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have biochemically confirmed HPT and surgery is planned, ask your care team about FCH PET\/CT as a first-line imaging option\u003c\/strong\u003e — not just as a backup when ultrasound or MIBI fails. The evidence supports first-line use in all types of HPT, including primary, renal, persistent, and recurrent disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have had a previous failed parathyroidectomy\u003c\/strong\u003e, FCH PET\/CT is particularly valuable for locating the remaining abnormal gland(s) before reoperation, given the high complication risk of repeat surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have renal (secondary) HPT or a hereditary condition like MEN1\u003c\/strong\u003e, FCH PET\/CT is strongly recommended because of its superior ability to detect multiple hyperplastic glands, which are common in these conditions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you were told your MIBI scan was negative or inconclusive\u003c\/strong\u003e, this does not mean imaging cannot help you. FCH PET\/CT successfully localizes abnormal glands in many patients with negative MIBI results.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss the \"one-stop shop\" approach with your surgeon\u003c\/strong\u003e — going straight to FCH PET\/CT may avoid multiple rounds of imaging and reduce total radiation exposure, with similar or better cost-effectiveness compared with sequential imaging strategies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf parathyroid carcinoma is suspected\u003c\/strong\u003e (based on very high PTH, calcium \u0026gt;3 mmol\/L, or a neck mass larger than 3 cm), FCH PET\/CT can help guide surgical planning and detect recurrent or metastatic disease.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eEvery patient's situation is unique, and imaging decisions should always be made together with your endocrinologist and surgeon. But the evidence in this review strongly supports the growing role of FCH PET\/CT as the first-line nuclear medicine imaging technique for all types of hyperparathyroidism when surgery is being considered.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is FCH PET\/CT and how does it work?\u003c\/h3\u003e\n\u003cp\u003eFCH PET\/CT is a modern imaging scan that uses a radioactive form of choline to locate overactive parathyroid glands before surgery. Overactive parathyroid cells take up this tracer more avidly than normal tissue, creating a 'hot spot' that appears on the scan. This helps surgeons know exactly where to look, improving surgical planning.\u003c\/p\u003e\n\u003ch3\u003eHow accurate is FCH PET\/CT compared with ultrasound or MIBI scans?\u003c\/h3\u003e\n\u003cp\u003eFCH PET\/CT detects abnormal parathyroid glands with about 97% sensitivity overall. In real-world data, ultrasound was positive in 47% of cases and MIBI scintigraphy in 37%. FCH PET\/CT consistently outperformed these older methods, meaning it is more likely to find the problem gland before surgery.\u003c\/p\u003e\n\u003ch3\u003eWill FCH PET\/CT reduce my chance of needing a second surgery?\u003c\/h3\u003e\n\u003cp\u003eYes. In a randomized trial, 85% of patients whose surgery was guided by FCH PET\/CT had normal calcium one month later, compared with 56% guided by MIBI. FCH PET\/CT also detects multiple abnormal glands far better than MIBI, reducing the chance that a missed gland causes a second operation.\u003c\/p\u003e\n\u003ch3\u003eIs FCH PET\/CT safe in terms of radiation exposure?\u003c\/h3\u003e\n\u003cp\u003eFCH PET\/CT involves radiation, but a single scan means lower cumulative radiation than having both MIBI and FCH scans sequentially. The FCH tracer has been used in Europe for over 20 years. Your care team will consider the benefits of accurate localization against the small radiation risk.\u003c\/p\u003e\n\u003ch3\u003eWho should get an FCH PET\/CT scan?\u003c\/h3\u003e\n\u003cp\u003eThe evidence supports FCH PET\/CT as a first-line imaging option for all types of hyperparathyroidism when surgery is planned. It is especially recommended for renal (secondary) hyperparathyroidism, hereditary conditions like MEN1, and patients with persistent or recurrent disease after prior surgery.\u003c\/p\u003e\n\u003ch3\u003eDoes FCH PET\/CT still work after a failed parathyroidectomy?\u003c\/h3\u003e\n\u003cp\u003eYes. In patients with suspected persistence or recurrence, FCH PET\/CT was positive in 78% of cases, nearly the same as in patients without prior surgery (84%). It also outperformed 4D-CT in this setting, making it a valuable tool before repeat surgery, which carries higher risk.\u003c\/p\u003e\n\u003ch3\u003eIs FCH PET\/CT worth the extra cost compared with other scans?\u003c\/h3\u003e\n\u003cp\u003eAlthough FCH PET\/CT costs more per dose than MIBI, studies in the US and Dutch healthcare systems found it cost-effective. In a US model, FCH PET\/CT gained the most quality-adjusted life-years and MIBI was less effective and more costly overall. Better accuracy can prevent failed surgeries and repeat procedures.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e 18F-Fluorocholine-Positron Emission\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Lucia Noskovicova, Sona Balogova, Cyrielle Aveline, Marc Tassart, Jules Zhang-Yin, Khaldoun Kerrou, Ivan Jaksic, Françoise Montravers, Jean-Noël Talbot\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Seminars in Nuclear Medicine (2024, in press). DOI: 10.1053\/j.semnuclmed.2024.08.002\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Departments of Nuclear Medicine at Comenius University Bratislava \/ St. Elisabeth Oncology Institute and Bory Hospital, Slovakia; Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France; Clinique Sud Luxembourg, Belgium; and Institut National des Sciences et Techniques Nucléaires (INSTN), Saclay, France.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. It has been written in plain language while preserving the key data and findings from the original publication. It is intended for educational purposes and is not a substitute for individualized medical advice from your healthcare team.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47405674037404,"sku":null,"price":0.0,"currency_code":"CHF","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ch\/it\/products\/fch-pet-ct-imaging-for-parathyroid-gland-detection-a-patients-guide-to-modern-pre-surgical-scanning","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}